Skip to content

STEMLINE THERAPEUTICS INC: 10-Q filed 2017-08-08

What STEMLINE THERAPEUTICS INC reported in its quarterly report filed 2017-08-08 (fiscal Q2 2017): 28 published measures, 76 facts as tagged in accession 0001104659-17-050286.

This filing

Form
10-Q (quarterly report)
Filed
2017-08-08
Fiscal period
fiscal Q2 2017
Accession
0001104659-17-050286 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All STEMLINE THERAPEUTICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-06-3093,973,551USD
At 2016-12-3168,119,098USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-06-3014,000,165USD
At 2016-12-3110,396,013USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-06-3079,973,386USD
At 2016-12-3157,723,085USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-06-308,549,890USD
At 2016-12-3110,316,064USD
At 2016-06-3012,769,184USD
At 2015-12-3113,376,196USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-01-01 to 2017-06-30-22,562,432USD181
2016-01-01 to 2016-06-30-16,396,246USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-01-01 to 2017-06-3048,339,843USD181
2016-01-01 to 2016-06-30104,684USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2017-01-01 to 2017-06-30-27,543,585USD181
2016-01-01 to 2016-06-3015,684,550USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-06-30-166,470,242USD
At 2016-12-31-135,742,607USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-26,756USD91
2016-01-01 to 2016-06-30-26,756USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-06-3045,773USD
At 2016-12-3122,531USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-06-303,929,092USD181
2016-01-01 to 2016-06-302,948,935USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-15,660,259USD91
2017-01-01 to 2017-06-30-30,348,958USD181
2016-04-01 to 2016-06-30-9,499,708USD91
2016-01-01 to 2016-06-30-18,692,909USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-06-3064,557,870USD
At 2016-12-3147,169,711USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-06-3013,893,515USD
At 2016-12-3110,253,813USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-04-01 to 2017-06-3011,479,030USD91
2017-01-01 to 2017-06-3021,099,354USD181
2016-04-01 to 2016-06-306,875,970USD91
2016-01-01 to 2016-06-3013,408,700USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-06-3025,180,024shares
At 2016-12-3119,219,223shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-06-30-120,897USD
At 2017-03-31-92,192USD
At 2016-12-31-99,802USD
At 2016-06-30-35,159USD
At 2016-03-3111,970USD
At 2015-12-31-153,690USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2017-06-30511,731USD
At 2016-12-31486,586USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-06-30465,958USD
At 2016-12-31464,055USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-06-30212,305USD
At 2016-12-31212,305USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-06-30106,650USD
At 2016-12-31142,200USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-06-30471,880USD
At 2016-12-31290,747USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-15,456,936USD91
2017-01-01 to 2017-06-30-30,022,946USD181
2016-04-01 to 2016-06-30-9,348,899USD91
2016-01-01 to 2016-06-30-18,397,443USD182

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-15,485,641USD91
2017-01-01 to 2017-06-30-30,044,041USD181
2016-04-01 to 2016-06-30-9,369,272USD91
2016-01-01 to 2016-06-30-18,252,156USD182

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-04-01 to 2017-06-30-15,456,936USD91
2017-01-01 to 2017-06-30-30,022,946USD181
2003-08-08 to 2017-06-30177,900,000USD5076
2016-04-01 to 2016-06-30-9,322,143USD91
2016-01-01 to 2016-06-30-18,370,687USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-04-01 to 2017-06-304,480,630USD91
2017-01-01 to 2017-06-309,848,406USD181
2016-04-01 to 2016-06-302,860,639USD91
2016-01-01 to 2016-06-305,726,761USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-04-01 to 2017-06-30953USD91
2017-01-01 to 2017-06-301,905USD181
2016-04-01 to 2016-06-3039,231USD91
2016-01-01 to 2016-06-3078,355USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2017-01-01 to 2017-06-3048,242,214USD181

Inspect the source

Entity
STEMLINE THERAPEUTICS INC / CIK 0001264587
Captured
SEC response SHA-256
4bc563f579ac3611fca3a4b0f91dded31bf19c0e78ed6a10086fa540610de496

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001264587.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))